

Clinical trials of propafenone

TrialResults-center www.trialresultscenter.org

1 atrial fibrillation

| Trial | Treatments | Patients | Trials design and methods |
|--|---|---|---------------------------------|
| propafenone vs placebo | | | |
| Bellandi (propafenone vs placebo) , 2001 n=102/92 follow-up: 12 months | Propafenone 900 mg/d/d after pharmacological or electrical cardioversion versus placebo | patients with paroxysmal recurrent or persistent AF | Parallel groups double blind |
| Dogan , 2004 n=58/52 follow-up: 15 months | Propafenone 450 mg/d versus placebo | AF of duration 3 hours to 3 months ??? | Parallel groups single |
| Kochiadakis b (propafenone vs placebo) , 2004 n=86/83 follow-up: 24 months | Propafenone 450 mg/d versus placebo | Any documented symptomatic previous or persistent AF | Parallel groups single |
| RAFT , 2003 n=397/126 follow-up: 9 months | Propafenone at various doses (450, 650, 850 mg/d) versus placebo. | Previous symptomatic AF documented in the last year | Parallel groups double blind |
| Stroobandt , 1997 n=77/25 follow-up: 6 months | Propafenone 450 mg/d versus placebo | Recent-onset AF or persistent AF lasting >2 weeks | Parallel groups double blind |
| propafenone vs flecainide | | | |
| FAPIS , 1996 n=97/103 follow-up: 12 months | propafenone 520 mg/dt versus Flecainide 200 mg/d | Paroxysmal recurrent AF with >2 episodes in the last 4 months | Parallel groups open |
| propafenone vs quinidine | | | |
| Richiardi , 1992 n=98/102 follow-up: 12 months | Propafenone 900 mg/d versus Quinidine 1 g/d mg/d | Paroxysmal AF having >3 episodes in the last 3 months | Parallel groups open |
| propafenone vs sotalol | | | |
| Reimold , 1993 n=50/50 follow-up: 12 months | Propafenone 675 mg/d versus Sotalol 320 mg/d | Any symptomatic AF or AF _l x-bitm | Parallel groups open |

More details and results :

- antiarrhythmic drugs for atrial fibrillation in maintaining sinus rhythm after cardioversion at <http://www.trialresultscenter.org/go-Q113>

References

Bellandi (propafenone vs placebo), 2001:

Bellandi F, Simonetti I, Leoncini M, Frascarelli F, Giovannini T, Maioli M, Dabizzi RP Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. *Am J Cardiol* 2001;88:640-5 [[11564387](#)]

Bellandi F, Dabizzi RP, Niccoli L, Cantini F, Palchetti R [Propafenone and sotalol: long-term efficacy and tolerability in the prevention of paroxysmal atrial fibrillation. A placebo-controlled double-blind study] *G Ital Cardiol* 1996;26:379-90 [[8707022](#)]

Bellandi F, Dabizzi RP, Niccoli L, Cantini F, Palchetti R [Propafenone and sotalol: long-term efficacy and tolerability in the prevention of paroxysmal atrial fibrillation. A placebo-controlled double-blind study] *G Ital Cardiol* 1996;26:379-90 [[8707022](#)]

Dogan, 2004:

Dogan A, Ergene O, Nazli C, Kinay O, Altinbas A, Ucarci Y, Ergene U, Ozaydin M, Gedikli O Efficacy of propafenone for maintaining sinus rhythm in patients with recent onset or persistent atrial fibrillation after conversion: a randomized, placebo-controlled study. *Acta Cardiol* 2004;59:255-61 [[15255456](#)]

Kochiadakis b (propafenone vs placebo), 2004:

Kochiadakis GE, Igoumenidis NE, Hamilos ME, Tzerakis PG, Klapsinos NC, Chlouverakis GI, Vardas PE Sotalol versus propafenone for long-term maintenance of normal sinus rhythm in patients with recurrent symptomatic atrial fibrillation. *Am J Cardiol* 2004;94:1563-6 [[15589019](#)]

Kochiadakis GE, Igoumenidis NE, Hamilos ME, Tzerakis PG, Klapsinos NC, Chlouverakis GI, Vardas PE *Am J Cardiol* 2004;94:1563-6 [[15589019](#)] [10.1016/j.amjcard.2004.08.041](https://doi.org/10.1016/j.amjcard.2004.08.041)

RAFT, 2003:

Pritchett EL, Page RL, Carlson M, Undesser K, Fava G Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. *Am J Cardiol* 2003;92:941-6 [[14556870](#)]

Stroobandt, 1997:

Stroobandt R, Stiels B, Hoebrechts R Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators. *Am J Cardiol* 1997;79:418-23 [[9052343](#)]

FAPIS, 1996:

Chimienti M, Cullen MT Jr, Casadei G Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. *Eur Heart J* 1995;16:1943-51 [[8682031](#)]

Chimienti M, Cullen MT Jr, Casadei G Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators. *Am J Cardiol* 1996;77:60A-75A [[8607393](#)]

Richiardi, 1992:

Richiardi E, Gaita F, Greco C, Gaschino G, Comba Costa G, Rosettani E, Brusca A [Propafenone versus hydroquinidine in long-term pharmacological prophylaxis of atrial fibrillation] *Cardiologia* 1992;37:123-7 [[1600529](#)]

Reimold, 1993:

Reimold SC, Cantillon CO, Friedman PL, Antman EM Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993;71:558-63 [8438741]

Entry terms: Propafenone, Propamerck, Rythmol, Arythmol, Rytmonorm, Norfenon, Pintoform, Propafenon Minden, Rytmo-Puren, Ryt-mogenat, Baxarytmon, Cuxafenon, Fenoprain, Jutanorm, Nistaken, Prolecofen, ,